Journal
ACS BIOMATERIALS SCIENCE & ENGINEERING
Volume 1, Issue 9, Pages 753-759Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsbiomaterials.5b00077
Keywords
coacervate; controlled release; hydrogel; interleukin-10; myocardial infarction; sonic hedgehog
Categories
Funding
- Whitaker Foundation
- South African Medical Research Council [415626]
- South African National Research Foundation [78802]
- National Institutes of Health [2T32HL076124]
- National Science Foundation [DMR 1005766]
- American Heart Association [12EIA9020016]
Ask authors/readers for more resources
Regenerative therapies to improve prognosis after heart attack and mitigate the onset of heart failure are urgently needed. To this end, we developed a bioactive therapy of sustained release of the morphogen Sonic hedgehog (Shh) and the anti-inflammatory cytokine interleukin-10 (IL-10) from a coacervate delivery vehicle. This is combined with a structural therapy consisting of a biodegradable polyethylene glycol (PEG) hydrogel, harnessing the benefits of both components. Upon injection into the hearts of rats after heart attack, we found that each component synergistically improved the benefit of the other. Furthermore, their combination was critical to preserve heart function. These findings indicate that, when combined, growth factor delivery and an injectable hydrogel represent a promising therapeutic approach for treatment after heart attack.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available